The Lancet
Landmark RCT of 20,211 trauma patients across 274 hospitals in 40 countries. Tranexamic acid reduced all-cause mortality by 1.5% absolute (14.5% vs 16.0%) and death due to bleeding by nearly a third. Now standard of care in trauma and surgical settings worldwide.
All-cause mortality was significantly reduced with tranexamic acid (1463 [14.5%] vs 1613 [16.0%]; relative risk 0.91, 95% CI 0.85–0.97; p=0.0035).